Realtime | Geld | Brief | Zeit |
---|---|---|---|
5,150 | 5,350 | 23:00 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | WUXI XDC (02268): NOTICE OF BOARD MEETING | 1 | HKEx | ||
27.06. | WUXI XDC (02268): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
27.06. | WUXI XDC (02268): (1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 27, 2025; (2) CHANGE OF DIRECTORS; AND (3) CHANGE IN COMPOSITION OF BOARD ... | - | HKEx | ||
28.05. | WUXI XDC (02268): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 27, 2025 | 1 | HKEx | ||
28.05. | WUXI XDC (02268): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
28.05. | WUXI XDC (02268): (1) PROPOSED RE-ELECTION AND APPOINTMENT OF DIRECTORS (2) PROPOSED GRANT OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES AND ... | 1 | HKEx | ||
28.05. | WUXI XDC (02268): CHANGE OF DATE OF ANNUAL GENERAL MEETING AND BOOK CLOSURE PERIOD | 1 | HKEx | ||
WUXI XDC Aktie jetzt für 0€ handeln | |||||
29.04. | WUXI XDC (02268): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2024 | - | HKEx | ||
29.04. | WUXI XDC (02268): ANNUAL REPORT 2024 | - | HKEx | ||
14.04. | WUXI XDC (02268): GRANT OF RESTRICTED SHARES UNDER THE 2024 SHARE SCHEME | - | HKEx | ||
25.03. | Contractors WuXi Bio, WuXi XDC eye continued growth after logging solid performances in 2024 | 5 | FiercePharma | ||
24.03. | WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024 | 155 | PR Newswire | Revenue increased by 90.8% YoY to RMB 4,052 million
Gross profit grew by 121.6% YoY to RMB 1,240 million, with its margin of 30.6%, a 4.3 percentage points increase compared to that... ► Artikel lesen | |
24.03. | WUXI XDC (02268): INSIDE INFORMATION 2024 ANNUAL RESULTS PRESENTATION | 1 | HKEx | ||
24.03. | WUXI XDC (02268): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 | 1 | HKEx | ||
12.03. | WuXi XDC and AbTis collaborate on antibody-drug conjugates | 1 | Pharmaceutical Technology | ||
03.03. | WUXI XDC (02268): NOTICE OF BOARD MEETING | - | HKEx | ||
15.01. | BRIEF: WuXi XDC's revenue, profit jump in 2024 | 1 | Bamboo Works | ||
15.01. | WUXI XDC (02268): POSITIVE PROFIT ALERT | 1 | HKEx | ||
20.08.24 | WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth | 382 | PR Newswire | Revenue surged by 67.6% YoY to RMB 1,665 million
Gross profit surged by 133.4% to RMB 535 million, with a gross profit margin of 32.1%, a 9.0 percentage points increase compared to 1H 2023.
Net profit... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
VALNEVA | 2,690 | +3,62 % | Valneva mit Kurssprung - das ist der Grund | Die Aktie von Valneva kann zum Wochenstart kräftig zulegen. Grund für den Kurssprung sind positive Neuigkeiten von der Europäischen Arzneimittelagentur (EMA). Diese hat die im Mai verhängte Restriktion... ► Artikel lesen | |
EPIGENOMICS | 0,850 | 0,00 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2025 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
Epigenomics AG: Vorläufiges Halbjahresergebnis... ► Artikel lesen | |
AAP IMPLANTATE | 2,080 | +11,83 % | EQS-News: aap Implantate AG schließt das Geschäftsjahr 2024 erfolgreich ab - positive Entwicklungen trotz herausforderndem Umfeld | EQS-News: aap Implantate AG
/ Schlagwort(e): Jahresbericht
aap Implantate AG schließt das Geschäftsjahr 2024 erfolgreich ab - positive Entwicklungen trotz herausforderndem Umfeld... ► Artikel lesen | |
INFLARX | 0,756 | +0,13 % | InflaRx N.V.: InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement | JENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,440 | +0,92 % | Defence Therapeutics Inc.: Defence's Accum Technology with ADC and Radiopharmaceutical Programs Target Cancer | Montreal, Quebec--(Newsfile Corp. - July 14, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
MICROBOT MEDICAL | 2,180 | -1,98 % | Microbot Medical Inc. - 8-K, Current Report | ||
ALDEYRA | 4,202 | +5,74 % | Hagens Berman Sobol Shapiro LLP: Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman | SAN FRANCISCO, April 10, 2025 /PRNewswire/ -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over... ► Artikel lesen | |
IMMUNIC | 0,706 | -0,56 % | Immunic: Verwaltungsrat genehmigt bis zu 35 Millionen Stock Appreciation Rights für Mitarbeiter | ||
ONCO-INNOVATIONS | 1,200 | -0,83 % | Onco-Innovations stärkt seine klinische Führungskompetenz durch die Ernennung von Dr. Islam Mohamed zum Advisory Board Chair | Vancouver, Kanada - 10. Juli 2025 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") freut sich, die Ernennung von Dr. Islam Mohamed
... ► Artikel lesen | |
CELLECTIS | 1,806 | +37,23 % | Cellectis Reports Financial Results for the First Quarter 2025 | Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma... ► Artikel lesen | |
ESPERION | 1,023 | 0,00 % | Esperion Therapeutics, Inc.: Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040 | ANN ARBOR, Mich., July 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Accord Healthcare Inc. This agreement resolves the... ► Artikel lesen | |
VERASTEM | 4,000 | -0,50 % | Verastem-Aktie legt zu: Positive Studiendaten zu Eierstockkrebs-Therapie veröffentlicht | ||
SAGE THERAPEUTICS | 7,816 | 0,00 % | Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock | ||
UNITY BIOTECHNOLOGY | 0,064 | -34,79 % | UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates | SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of... ► Artikel lesen | |
MESOBLAST | 0,900 | 0,00 % | MESOBLAST LIMITED: Notification of cessation of securities - MSB |